Literature DB >> 24292674

PPARγ E3 ubiquitin ligase regulates MUC1-C oncoprotein stability.

Y Hou1, J Gao1, H Xu1, Y Xu1, Z Zhang1, Q Xu1, C Zhang1.   

Abstract

MUC1-C oncoprotein is associated with colon, breast, ovarian, lung and pancreatic cancers. MUC1-C interacts with intracellular proteins to elicit signaling cascades that induce cell proliferation and tumor growth. Here we report that peroxisome proliferator-activated receptor gamma (PPARγ), an E3 ubiquitin ligase, is an inhibitor of MUC1-C-mediated cell proliferation. PPARγ does so by binding to and inducing MUC1-C proteasome-dependent degradation that was independent of PPARγ transcriptional activity. Lys134 residue was found to be critically important for PPARγ-mediated MUC1-C degradation, as it terminated MUC1-C-mediated cell proliferation. These findings demonstrate PPARγ induces MUC1-C ubiquitination and degradation that is critical to terminate MUC1-C signaling pathway-elicited cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24292674     DOI: 10.1038/onc.2013.504

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  Ubiquitin-mediated NFκB degradation pathway.

Authors:  Huimin Xu; Mengli You; Haifeng Shi; Yongzhong Hou
Journal:  Cell Mol Immunol       Date:  2014-10-27       Impact factor: 11.530

2.  PPARδ is a regulator of autophagy by its phosphorylation.

Authors:  Qian Gou; Yidan Jiang; Runyun Zhang; Ying Xu; Huihui Xu; Wenbo Zhang; Juanjuan Shi; Yongzhong Hou
Journal:  Oncogene       Date:  2020-05-21       Impact factor: 9.867

Review 3.  Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.

Authors:  Simone Polvani; Mirko Tarocchi; Sara Tempesti; Lapo Bencini; Andrea Galli
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

Review 4.  Inhibitor of growth-4 is a potential target for cancer therapy.

Authors:  Shuping Yuan; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Tumour Biol       Date:  2016-01-23

5.  Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.

Authors:  Jing Li; SongTao Xiang; QiouHong Zhang; JingJing Wu; Qing Tang; JianFu Zhou; LiJun Yang; ZhiQiang Chen; Swei Sunny Hann
Journal:  J Exp Clin Cancer Res       Date:  2015-05-15

6.  Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells.

Authors:  H-L Huang; H-Y Wu; P-C Chu; I-L Lai; P-H Huang; S K Kulp; S-L Pan; C-M Teng; C-S Chen
Journal:  Oncogenesis       Date:  2017-07-10       Impact factor: 7.485

7.  A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients.

Authors:  Aryo D Pamungkas; Carl A Medriano; Eunjung Sim; Sungyong Lee; Youngja H Park
Journal:  Mol Med Rep       Date:  2017-04-28       Impact factor: 2.952

8.  Naoxintong/PPARγ Signaling Inhibits Cardiac Hypertrophy via Activation of Autophagy.

Authors:  Shuping Yuan; Jianhua Jin; Lu Chen; Yongzhong Hou; Hong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-15       Impact factor: 2.629

9.  Degradation of selenoprotein S and selenoprotein K through PPARγ-mediated ubiquitination is required for adipocyte differentiation.

Authors:  Jea Hwang Lee; Jun Ki Jang; Kwan Young Ko; Yunjung Jin; Minju Ham; Hyunwoo Kang; Ick Young Kim
Journal:  Cell Death Differ       Date:  2018-08-06       Impact factor: 15.828

10.  Naoxintong/PPARα Signaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress.

Authors:  Huimin Xu; Jianhua Jin; Lu Chen; Chunxiao Li; Qinggang Xu; Juanjuan Shi; Buchang Zhao; Yongzhong Hou; Hong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-07       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.